KR20200044023A - 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물 - Google Patents

항-베타 아밀로이드 항체를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR20200044023A
KR20200044023A KR1020207007477A KR20207007477A KR20200044023A KR 20200044023 A KR20200044023 A KR 20200044023A KR 1020207007477 A KR1020207007477 A KR 1020207007477A KR 20207007477 A KR20207007477 A KR 20207007477A KR 20200044023 A KR20200044023 A KR 20200044023A
Authority
KR
South Korea
Prior art keywords
concentration
pharmaceutical composition
composition
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207007477A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 앤드류 란츠
카필 굽타
샨타누 술레
애드난 주닉
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Priority to KR1020257011023A priority Critical patent/KR20250053967A/ko
Publication of KR20200044023A publication Critical patent/KR20200044023A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207007477A 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물 Pending KR20200044023A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257011023A KR20250053967A (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548583P 2017-08-22 2017-08-22
US62/548,583 2017-08-22
PCT/US2018/047508 WO2019040612A1 (en) 2017-08-22 2018-08-22 PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257011023A Division KR20250053967A (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
KR20200044023A true KR20200044023A (ko) 2020-04-28

Family

ID=63449734

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257011023A Pending KR20250053967A (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물
KR1020207007477A Pending KR20200044023A (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020257011023A Pending KR20250053967A (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물

Country Status (29)

Country Link
US (2) US11655289B2 (enExample)
EP (2) EP4233901A3 (enExample)
JP (3) JP7263320B2 (enExample)
KR (2) KR20250053967A (enExample)
CN (2) CN111201037B (enExample)
AU (1) AU2018321335B2 (enExample)
BR (1) BR112020003572A2 (enExample)
CA (1) CA3073066A1 (enExample)
CO (1) CO2020002992A2 (enExample)
DK (1) DK3672631T5 (enExample)
EA (1) EA202090555A1 (enExample)
ES (1) ES2945165T3 (enExample)
FI (1) FI3672631T3 (enExample)
HR (1) HRP20230387T1 (enExample)
HU (1) HUE061510T2 (enExample)
IL (1) IL272773B2 (enExample)
JO (1) JOP20200041A1 (enExample)
LT (1) LT3672631T (enExample)
MA (1) MA49947B1 (enExample)
MD (1) MD3672631T3 (enExample)
MX (2) MX2020001855A (enExample)
MY (1) MY204563A (enExample)
PL (1) PL3672631T3 (enExample)
PT (1) PT3672631T (enExample)
RS (1) RS64289B1 (enExample)
SG (1) SG11202001281WA (enExample)
SI (1) SI3672631T1 (enExample)
SM (1) SMT202300129T1 (enExample)
WO (1) WO2019040612A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250136262A (ko) 2024-03-06 2025-09-16 일리미스테라퓨틱스 주식회사 엔지니어링된 tam 수용체 리간드 폴리펩티드 및 이의 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
KR20210089179A (ko) * 2018-10-26 2021-07-15 카파 테라퓨틱스 리미티드 Cll1을 표적으로 하는 항체 및 이의 응용
UY38605A (es) * 2019-03-11 2020-09-30 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1
CN113891746B (zh) 2019-03-26 2025-05-06 詹森药业有限公司 焦谷氨酸淀粉样蛋白-β的抗体及其用途
IL300059A (en) 2020-07-23 2023-03-01 Othair Prothena Ltd Anti-Abata antibodies
JP2025540137A (ja) * 2022-12-02 2025-12-11 シアトル プロジェクト コーポレイション 組成物及びその使用方法
AR133829A1 (es) 2023-09-15 2025-11-05 Othair Prothena Ltd Agentes penetrantes de células y usos de los mismos
WO2025064824A1 (en) * 2023-09-22 2025-03-27 Biogen Ma Inc. Methods for treating alzheimer's disease

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
CA2174429C (en) 1993-10-27 2011-08-30 Lisa C. Mcconlogue Transgenic animals harboring app allele having swedish mutation
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
PL193447B1 (pl) 1996-12-24 2007-02-28 Biogen Idec Inc Kompozycja interferonu, kompozycja farmaceutycznainterferonu oraz sposób stabilizowania kompozycjiinterferonu
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2344189T3 (es) 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
US6187309B1 (en) 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
DE60028233T2 (de) 1999-10-27 2007-03-08 Universite De Liege Immuno-real-time-pcr unter verwendung einer chimären dna als amplifikationsmarker
DE60140252D1 (de) 2000-06-22 2009-12-03 Genentech Inc Agonistische monoklonale antikörper gegen trkc
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030028904A1 (en) 2001-04-19 2003-02-06 Gumienny Tina L. Genes involved in engulfment of dying cells and cell migration
AU2002329775C1 (en) 2001-08-17 2011-04-07 Eli Lilly And Company Assay method for alzheimer's disease
US7414111B2 (en) 2001-09-19 2008-08-19 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2368907T3 (es) 2002-04-19 2011-11-23 The Governing Council Of The University Of Toronto Procedimientos y composiciones inmunológicas para el tratamiento de la enfermedad de alzheimer.
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4690046B2 (ja) 2002-11-22 2011-06-01 中外製薬株式会社 病巣組織に対する抗体
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20060240485A1 (en) 2003-04-24 2006-10-26 Universitat Zurich Method of monitoring immunotherapy
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
UA93181C2 (ru) 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
US7456027B2 (en) 2004-04-15 2008-11-25 University Of Florida Research Foundation, Inc. Proteolytic biomarkers for traumatic injury to the nervous system
JPWO2005105998A1 (ja) 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
ATE476993T1 (de) 2004-06-07 2010-08-15 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
CA2589017A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
CN101365717A (zh) 2005-03-05 2009-02-11 艾博特股份有限两合公司 筛选方法、纯化非扩散A-β寡聚体的方法、抗所述非扩散A-β寡聚体的选择性抗体以及制备所述抗体的方法
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
WO2006116192A2 (en) 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
CA2629463A1 (en) 2005-11-14 2008-02-21 Scott A. Small Imaging correlates of neurogenesis with mri
WO2007062088A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007064917A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HUE034512T2 (en) 2007-01-05 2018-02-28 Univ Zuerich A method for providing disease-specific binding molecules and targets
AR064826A1 (es) 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
ES2523194T3 (es) 2007-03-13 2014-11-21 University Of Zurich Anticuerpo monoclonal humano específico para cada tumor
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR20100016661A (ko) 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 대뇌 아밀로이드 혈관병증의 예방 및 치료
JP2008309778A (ja) 2007-05-11 2008-12-25 Daiichi Sankyo Co Ltd ポリペプチドの検出又は定量方法、及び装置
AU2008258503A1 (en) 2007-06-08 2008-12-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for treating pancreatic tumors
US8022268B2 (en) 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
JP2010536907A (ja) 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
CA2696417A1 (en) 2007-10-02 2009-04-09 Csl Limited Therapeutic antibody purification method and method of use
US7771957B2 (en) 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
UA103602C2 (ru) 2007-10-29 2013-11-11 Енсерм (Енстітю Насьональ Де Ля Санте Е Де Ля Решер Медікалє) АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА
MY158903A (en) 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
AU2009211635B2 (en) 2008-02-08 2014-06-26 National Center For Geriatrics And Gerontology Antibody capable of binding specifically to Abeta-oligomer, and use thereof
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
BRPI0918555A2 (pt) 2008-09-19 2016-05-03 Medimmune Llc anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
CA2742771A1 (en) 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
BRPI0923157B1 (pt) 2008-12-19 2021-12-28 University Of Zürich Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
US20110237537A1 (en) 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
CA2765220A1 (en) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
JP2013511734A (ja) 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
WO2011076854A1 (en) 2009-12-22 2011-06-30 Probiodrug Ag CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
WO2012005838A1 (en) 2010-07-07 2012-01-12 Thermo Fisher Scientific Gmbh Analyte mass spectrometry quantitation using a universal reporter
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
WO2012174262A2 (en) 2011-06-14 2012-12-20 Cenestra Llc Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
JP6240611B2 (ja) 2011-10-28 2017-11-29 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
US20130164367A1 (en) 2011-12-08 2013-06-27 The Board Of Regents Of The University Of Texas System Treatment of neurodegenerative disease with creb-binding protein
DK2822587T3 (en) 2012-03-08 2016-02-29 Hoffmann La Roche ABETA ANTIBODY FORMULATION
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
CA2884581C (en) 2012-09-12 2024-01-23 Neurimmune Holding Ag Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof
HK1215673A1 (zh) * 2012-12-07 2016-09-09 Biogen International Neuroscience Gmbh 一個使用抗ab抗體減少腦部澱粉蛋白質斑的方法
US20140272950A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict ssri response
EP2968535A2 (en) 2013-03-15 2016-01-20 Glaxosmithkline Intellectual Property (No. 2) Limited Low concentration antibody formulations
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
WO2014182631A1 (en) 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
EP3019629A4 (en) 2013-07-12 2017-01-18 Biogen International Neuroscience GmbH Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
SG11201604831QA (en) 2013-12-20 2016-08-30 Neurimmune Holding Ag Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US20150246963A1 (en) 2014-02-08 2015-09-03 Genentech, Inc. Methods of treating alzheimer's disease
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
KR102643395B1 (ko) 2014-07-29 2024-03-11 뉴리뮨 홀딩 아게 인간-유래의 항-헌팅틴(htt) 항체 및 그의 용도
WO2016040903A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP4063858A1 (en) 2016-03-14 2022-09-28 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250136262A (ko) 2024-03-06 2025-09-16 일리미스테라퓨틱스 주식회사 엔지니어링된 tam 수용체 리간드 폴리펩티드 및 이의 용도

Also Published As

Publication number Publication date
SI3672631T1 (sl) 2023-06-30
CN111201037B (zh) 2024-04-02
KR20250053967A (ko) 2025-04-22
MD3672631T2 (ro) 2023-06-30
FI3672631T3 (fi) 2023-06-29
IL272773B2 (en) 2024-06-01
EA202090555A1 (ru) 2020-06-08
EP3672631B1 (en) 2023-03-29
US11655289B2 (en) 2023-05-23
EP3672631B9 (en) 2023-06-28
JOP20200041A1 (ar) 2020-02-20
SG11202001281WA (en) 2020-03-30
CO2020002992A2 (es) 2020-06-19
RS64289B1 (sr) 2023-07-31
EP4233901A2 (en) 2023-08-30
MA49947A (fr) 2021-04-21
EP3672631A1 (en) 2020-07-01
AU2018321335B2 (en) 2025-08-14
DK3672631T3 (da) 2023-07-03
MA49947B1 (fr) 2023-03-31
JP2023030173A (ja) 2023-03-07
CA3073066A1 (en) 2019-02-28
LT3672631T (lt) 2023-04-25
JP2025175284A (ja) 2025-12-01
MX2024010300A (es) 2024-08-28
JP7263320B2 (ja) 2023-04-24
US20240043513A1 (en) 2024-02-08
CN118370815A (zh) 2024-07-23
US20210188954A1 (en) 2021-06-24
JP2020531520A (ja) 2020-11-05
PT3672631T (pt) 2023-05-23
HUE061510T2 (hu) 2023-07-28
MD3672631T3 (ro) 2023-09-30
PL3672631T3 (pl) 2023-06-26
WO2019040612A1 (en) 2019-02-28
MY204563A (en) 2024-09-04
IL272773B1 (en) 2024-02-01
MX2020001855A (es) 2020-08-13
BR112020003572A2 (pt) 2020-08-25
AU2018321335A1 (en) 2020-02-27
CN111201037A (zh) 2020-05-26
ES2945165T3 (es) 2023-06-28
DK3672631T5 (da) 2024-08-26
IL272773A (en) 2020-04-30
SMT202300129T1 (it) 2023-05-12
HRP20230387T1 (hr) 2023-07-07
EP4233901A3 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20240043513A1 (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
EP1853310B1 (en) Anti a beta antibody formulation
AU2024203126A1 (en) Antibody formulation
JP2025512032A (ja) Ｐｄ－１抗体を含有する安定した高濃度アルギニン製剤及びその使用方法
HK40100459A (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
HK40022704B (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
HK40022704A (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
US20250084168A1 (en) Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK1108132B (en) Anti a beta antibody formulation
HK1163504A (en) Anti a beta antibody formulation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701